CO2
Phase 2Small molecule
CO2 is one of 36 small molecule programs targeting Headache. It is currently in Phase 2.
2
Indications
6
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
122 competitors in Seasonal Allergic Rhinitis
#DrugCompanyPhaseTrials
1Alvesco
AAzurity Pharmaceuticals
Phase 3
Xolair
RochePhase 3
Qvar
SSchering-Plough
Phase 3
Sudafed
KKenvue Brands
Phase 3
Bilaxten
MMenarini International Operations Luxembourg SA
Phase 3
Comparator: Statins
Merck & Co.Phase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
REGN5713
RegeneronPhase 3
REGN5715
RegeneronPhase 3
GW685698X
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Seasonal Allergic Rhinitis3 trials
Prevention1 trial
Carbon Dioxide1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CO2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCapnia, Inc.